Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Vorinostat + WP1066 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Vorinostat | Zolinza | SAHA|L-001079038|MSK390 | HDAC Inhibitor 45 | Zolinza (vorinostat) inhibits HDAC activity, resulting in cell-cycle arrest, decreased proliferation, and increased differentiation of tumor cells (PMID: 9501205, PMID: 11731433, PMID: 11016644). Zolinza (vorinostat) is FDA approved for use in cutaneous T-cell lymphoma (FDA.gov). |
WP1066 | JAK2 Inhibitor 19 STAT3 Inhibitor 26 | WP1066 is an inhibitor of JAK2, JAK2 V617F, and STAT3, which inhibits cell proliferation (PMID: 18245540, PMID: 21792892). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|